Research Paper Volume 12, Issue 13 pp 12750—12770

Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis

Figure 4. Dose-dependent elimination of senescent cells in OA chondrocytes (P1) isolated from human OA tissue after ABT263 treatment for 72h. (A) Schematic of the following experiment b–c. (B) SA-β-gal staining images shows a dose of 2.5 and 5.0μM effectively eliminated SA-β-gal positive senescent cells in OA chondrocytes (P1) by micromass culture in 48-well plates with increasing concentrations of ABT263 after different treatment time. Scale bar: 5 mm. (C) SA-β-gal positive cells were quantified 3 and 10 days following treatment with increasing concentrations of ABT263. Data are shown as mean ± standard deviation. N = 3 per group. **P < 0.01, ***P < 0.001 and n.s. (Not Significant); One-way ANOVA (Tukey’s multiple comparison test). N = 3 for 0, 0.313, 0.625, 1.25, 2.5, 5.0μM.